Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer

Journal of Proteome Research

Volumn 13, Issue 2, 2014, Pages 1088-1100

  Kaushik, Akash K ^a   Vareed, Shaiju K ^a   Basu, Sumanta ^b   Putluri, Vasanta ^a   Putluri, Nagireddy ^a   Panzitt, Katrin ^a   Brennan, Christine A ^d   Chinnaiyan, Arul M ^c   Vergara, Ismael A ^f   Erho, Nicholas ^f   Weigel, Nancy L ^a   Mitsiades, Nicholas ^a   Shojaie, Ali ^e   Palapattu, Ganesh ^c   Michailidis, George ^b   Sreekumar, Arun ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f GenomeDx Biosciences Inc   (Canada)

Author keywords

biochemical recurrence; castration resistant prostate cancer; liquid chromatography mass spectrometry; metabolic phenotyping; metabolomics; Oncomine concept map; prostate cancer

Indexed keywords

CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; GENE EXPRESSION; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MASS SPECTROMETRY; METABOLOMICS; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84893828789     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr401106h     Document Type: Article

References (56)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012 CA Cancer J. Clin. 2012, 62 (1) 10-29
2. Huggins, C.; Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate CA Cancer J. Clin. 1972, 22 (4) 232-40
3. Wang, X.; Yin, L.; Rao, P.; Stein, R.; Harsch, K. M.; Lee, Z.; Heston, W. D. Targeted treatment of prostate cancer J. Cell Biochem. 2007, 102 (3) 571-9
4. Ohlson, N.; Wikstrom, P.; Stattin, P.; Bergh, A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment Prostate 2005, 62 (4) 307-15
5. Westin, P.; Bergh, A. Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review Cancer Detect. Prev. 1998, 22 (5) 476-84
6. Uchio, E. M.; Aslan, M.; Wells, C. K.; Calderone, J.; Concato, J. Impact of biochemical recurrence in prostate cancer among US veterans Arch. Intern. Med. 2010, 170 (15) 1390-5
7. Ward, J. F.; Blute, M. L.; Slezak, J.; Bergstralh, E. J.; Zincke, H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J. Urol. 2003, 170 (5) 1872-6
8. Massie, C. E.; Lynch, A.; Ramos-Montoya, A.; Boren, J.; Stark, R.; Fazli, L.; Warren, A.; Scott, H.; Madhu, B.; Sharma, N.; Bon, H.; Zecchini, V.; Smith, D. M.; Denicola, G. M.; Mathews, N.; Osborne, M.; Hadfield, J.; Macarthur, S.; Adryan, B.; Lyons, S. K.; Brindle, K. M.; Griffiths, J.; Gleave, M. E.; Rennie, P. S.; Neal, D. E.; Mills, I. G. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis EMBO J. 2011, 30 (13) 2719-33
9. Wang, Q.; Li, W.; Zhang, Y.; Yuan, X.; Xu, K.; Yu, J.; Chen, Z.; Beroukhim, R.; Wang, H.; Lupien, M.; Wu, T.; Regan, M. M.; Meyer, C. A.; Carroll, J. S.; Manrai, A. K.; Janne, O. A.; Balk, S. P.; Mehra, R.; Han, B.; Chinnaiyan, A. M.; Rubin, M. A.; True, L.; Fiorentino, M.; Fiore, C.; Loda, M.; Kantoff, P. W.; Liu, X. S.; Brown, M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer Cell 2009, 138 (2) 245-56
10. Ngan, S.; Stronach, E. A.; Photiou, A.; Waxman, J.; Ali, S.; Buluwela, L. Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells Oncogene 2009, 28 (19) 2051-63
11. Velasco, A. M.; Gillis, K. A.; Li, Y.; Brown, E. L.; Sadler, T. M.; Achilleos, M.; Greenberger, L. M.; Frost, P.; Bai, W.; Zhang, Y. Identification and validation of novel androgen-regulated genes in prostate cancer Endocrinology 2004, 145 (8) 3913-24
12. Khan, A. P.; Poisson, L. M.; Bhat, V. B.; Fermin, D.; Zhao, R.; Kalyana-Sundaram, S.; Michailidis, G.; Nesvizhskii, A. I.; Omenn, G. S.; Chinnaiyan, A. M.; Sreekumar, A. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer Mol. Cell. Proteomics 2010, 9 (2) 298-312
13. Xu, L. L.; Su, Y. P.; Labiche, R.; Segawa, T.; Shanmugam, N.; McLeod, D. G.; Moul, J. W.; Srivastava, S. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes Int. J. Cancer 2001, 92 (3) 322-8
14. Segawa, T.; Nau, M. E.; Xu, L. L.; Chilukuri, R. N.; Makarem, M.; Zhang, W.; Petrovics, G.; Sesterhenn, I. A.; McLeod, D. G.; Moul, J. W.; Vahey, M.; Srivastava, S. Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells Oncogene 2002, 21 (57) 8749-58
15. Kaarbo, M.; Mikkelsen, O. L.; Malerod, L.; Qu, S.; Lobert, V. H.; Akgul, G.; Halvorsen, T.; Maelandsmo, G. M.; Saatcioglu, F. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells Cell Oncol. 2010, 32 (1-2) 11-27
16. Kobayashi, T.; Shimizu, Y.; Terada, N.; Yamasaki, T.; Nakamura, E.; Toda, Y.; Nishiyama, H.; Kamoto, T.; Ogawa, O.; Inoue, T. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation Prostate 2010, 70 (8) 866-74
17. Wu, Y.; Chhipa, R. R.; Cheng, J.; Zhang, H.; Mohler, J. L.; Ip, C. Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival Anticancer Res. 2010, 30 (10) 3895-901
18. Vellaichamy, A.; Sreekumar, A.; Strahler, J. R.; Rajendiran, T.; Yu, J.; Varambally, S.; Li, Y.; Omenn, G. S.; Chinnaiyan, A. M.; Nesvizhskii, A. I. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases PLoS One 2009, 4 (9) e7075
19. Sreekumar, A.; Poisson, L. M.; Rajendiran, T. M.; Khan, A. P.; Cao, Q.; Yu, J.; Laxman, B.; Mehra, R.; Lonigro, R. J.; Li, Y.; Nyati, M. K.; Ahsan, A.; Kalyana-Sundaram, S.; Han, B.; Cao, X.; Byun, J.; Omenn, G. S.; Ghosh, D.; Pennathur, S.; Alexander, D. C.; Berger, A.; Shuster, J. R.; Wei, J. T.; Varambally, S.; Beecher, C.; Chinnaiyan, A. M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 2009, 457 (7231) 910-4
20. Putluri, N.; Shojaie, A.; Vasu, V. T.; Nalluri, S.; Vareed, S. K.; Putluri, V.; Vivekanandan-Giri, A.; Byun, J.; Pennathur, S.; Sana, T. R.; Fischer, S. M.; Palapattu, G. S.; Creighton, C. J.; Michailidis, G.; Sreekumar, A. Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells PLoS One 2011, 6 (7) e21417
21. Subramanian, A.; Tamayo, P.; Mootha, V. K.; Mukherjee, S.; Ebert, B. L.; Gillette, M. A.; Paulovich, A.; Pomeroy, S. L.; Golub, T. R.; Lander, E. S.; Mesirov, J. P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (43) 15545-50
22. Rhodes, D. R.; Kalyana-Sundaram, S.; Mahavisno, V.; Varambally, R.; Yu, J.; Briggs, B. B.; Barrette, T. R.; Anstet, M. J.; Kincead-Beal, C.; Kulkarni, P.; Varambally, S.; Ghosh, D.; Chinnaiyan, A. M. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles Neoplasia 2007, 9 (2) 166-80
23. Glinsky, G. V.; Glinskii, A. B.; Stephenson, A. J.; Hoffman, R. M.; Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer J. Clin. Invest. 2004, 113 (6) 913-23
24. Sun, Y.; Goodison, S. Optimizing molecular signatures for predicting prostate cancer recurrence Prostate 2009, 69 (10) 1119-27
25. Taylor, B. S.; Schultz, N.; Hieronymus, H.; Gopalan, A.; Xiao, Y.; Carver, B. S.; Arora, V. K.; Kaushik, P.; Cerami, E.; Reva, B.; Antipin, Y.; Mitsiades, N.; Landers, T.; Dolgalev, I.; Major, J. E.; Wilson, M.; Socci, N. D.; Lash, A. E.; Heguy, A.; Eastham, J. A.; Scher, H. I.; Reuter, V. E.; Scardino, P. T.; Sander, C.; Sawyers, C. L.; Gerald, W. L. Integrative genomic profiling of human prostate cancer Cancer Cell 2010, 18 (1) 11-22
26. Belanger, A.; Pelletier, G.; Labrie, F.; Barbier, O.; Chouinard, S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans Trends Endocrinol. Metab. 2003, 14 (10) 473-9
27. Mackenzie, P. I.; Owens, I. S.; Burchell, B.; Bock, K. W.; Bairoch, A.; Belanger, A.; Fournel-Gigleux, S.; Green, M.; Hum, D. W.; Iyanagi, T.; Lancet, D.; Louisot, P.; Magdalou, J.; Chowdhury, J. R.; Ritter, J. K.; Schachter, H.; Tephly, T. R.; Tipton, K. F.; Nebert, D. W. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence Pharmacogenetics 1997, 7 (4) 255-69
28. Rhodes, D. R.; Yu, J.; Shanker, K.; Deshpande, N.; Varambally, R.; Ghosh, D.; Barrette, T.; Pandey, A.; Chinnaiyan, A. M. ONCOMINE: a cancer microarray database and integrated data-mining platform Neoplasia 2004, 6 (1) 1-6
29. Horoszewicz, J. S.; Leong, S. S.; Kawinski, E.; Karr, J. P.; Rosenthal, H.; Chu, T. M.; Mirand, E. A.; Murphy, G. P. LNCaP model of human prostatic carcinoma Cancer Res. 1983, 43 (4) 1809-18
30. Navone, N. M.; Olive, M.; Ozen, M.; Davis, R.; Troncoso, P.; Tu, S. M.; Johnston, D.; Pollack, A.; Pathak, S.; von Eschenbach, A. C.; Logothetis, C. J. Establishment of two human prostate cancer cell lines derived from a single bone metastasis Clin. Cancer Res. 1997, 3 (12 Pt 1) 2493-500
31. Culig, Z.; Hoffmann, J.; Erdel, M.; Eder, I. E.; Hobisch, A.; Hittmair, A.; Bartsch, G.; Utermann, G.; Schneider, M. R.; Parczyk, K.; Klocker, H. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system Br. J. Cancer 1999, 81 (2) 242-51
32. Wu, H. C.; Hsieh, J. T.; Gleave, M. E.; Brown, N. M.; Pathak, S.; Chung, L. W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells Int. J. Cancer 1994, 57 (3) 406-12
33. Zhang, X.; Morrissey, C.; Sun, S.; Ketchandji, M.; Nelson, P. S.; True, L. D.; Vakar-Lopez, F.; Vessella, R. L.; Plymate, S. R. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases PLoS One 2011, 6 (11) e27970
34. Tomlins, S. A.; Rhodes, D. R.; Yu, J.; Varambally, S.; Mehra, R.; Perner, S.; Demichelis, F.; Helgeson, B. E.; Laxman, B.; Morris, D. S.; Cao, Q.; Cao, X.; Andren, O.; Fall, K.; Johnson, L.; Wei, J. T.; Shah, R. B.; Al-Ahmadie, H.; Eastham, J. A.; Eggener, S. E.; Fine, S. W.; Hotakainen, K.; Stenman, U. H.; Tsodikov, A.; Gerald, W. L.; Lilja, H.; Reuter, V. E.; Kantoff, P. W.; Scardino, P. T.; Rubin, M. A.; Bjartell, A. S.; Chinnaiyan, A. M. The role of SPINK1 in ETS rearrangement-negative prostate cancers Cancer Cell 2008, 13 (6) 519-28
35. Dillies, M. A.; Rau, A.; Aubert, J.; Hennequet-Antier, C.; Jeanmougin, M.; Servant, N.; Keime, C.; Marot, G.; Castel, D.; Estelle, J.; Guernec, G.; Jagla, B.; Jouneau, L.; Laloe, D.; Le Gall, C.; Schaeffer, B.; Le Crom, S.; Guedj, M.; Jaffrezic, F.; French StatOmique Consortium. A comprehensive evaluation of normalization methods for Illumina high-throughput RNA sequencing data analysis Briefings Bioinform. 2012, 14 (6) 671-83
36. Bao, B. Y.; Chuang, B. F.; Wang, Q.; Sartor, O.; Balk, S. P.; Brown, M.; Kantoff, P. W.; Lee, G. S. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes Prostate 2008, 68 (8) 839-48
37. Paquet, S.; Fazli, L.; Grosse, L.; Verreault, M.; Tetu, B.; Rennie, P. S.; Belanger, A.; Barbier, O. Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression J. Clin. Endocrinol. Metab. 2012, 97 (3) E428-32
38. Grasso, C. S.; Wu, Y. M.; Robinson, D. R.; Cao, X.; Dhanasekaran, S. M.; Khan, A. P.; Quist, M. J.; Jing, X.; Lonigro, R. J.; Brenner, J. C.; Asangani, I. A.; Ateeq, B.; Chun, S. Y.; Siddiqui, J.; Sam, L.; Anstett, M.; Mehra, R.; Prensner, J. R.; Palanisamy, N.; Ryslik, G. A.; Vandin, F.; Raphael, B. J.; Kunju, L. P.; Rhodes, D. R.; Pienta, K. J.; Chinnaiyan, A. M.; Tomlins, S. A. The mutational landscape of lethal castration-resistant prostate cancer Nature 2012, 487 (7406) 239-43
39. Varambally, S.; Yu, J.; Laxman, B.; Rhodes, D. R.; Mehra, R.; Tomlins, S. A.; Shah, R. B.; Chandran, U.; Monzon, F. A.; Becich, M. J.; Wei, J. T.; Pienta, K. J.; Ghosh, D.; Rubin, M. A.; Chinnaiyan, A. M. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression Cancer Cell 2005, 8 (5) 393-406
40. Vanaja, D. K.; Cheville, J. C.; Iturria, S. J.; Young, C. Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression Cancer Res. 2003, 63 (14) 3877-82
41. Imielinski, M.; Cha, S.; Rejtar, T.; Richardson, E. A.; Karger, B. L.; Sgroi, D. C. Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse Mol. Cell. Proteomics 2012, 11 (6) M111 014910
42. Creighton, C. J. Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors PLoS One 2008, 3 (3) e1816
43. Ning, Q. Y.; Wu, J. Z.; Zang, N.; Liang, J.; Hu, Y. L.; Mo, Z. N. Key pathways involved in prostate cancer based on gene set enrichment analysis and meta analysis Genet. Mol. Res. 2011, 10 (4) 3856-87
44. Crawford, E. D.; Eisenberger, M. A.; McLeod, D. G.; Spaulding, J. T.; Benson, R.; Dorr, F. A.; Blumenstein, B. A.; Davis, M. A.; Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N. Engl. J. Med. 1989, 321 (7) 419-24
45. Eisenberger, M. A.; Blumenstein, B. A.; Crawford, E. D.; Miller, G.; McLeod, D. G.; Loehrer, P. J.; Wilding, G.; Sears, K.; Culkin, D. J.; Thompson, I. M., Jr.; Bueschen, A. J.; Lowe, B. A. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N. Engl. J. Med. 1998, 339 (15) 1036-42
46. Taplin, M. E.; Bubley, G. J.; Shuster, T. D.; Frantz, M. E.; Spooner, A. E.; Ogata, G. K.; Keer, H. N.; Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N. Engl. J. Med. 1995, 332 (21) 1393-8
47. Koivisto, P.; Visakorpi, T.; Kallioniemi, O. P. Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer Scand. J. Clin. Lab. Invest. Suppl. 1996, 226, 57-63
48. Veldscholte, J.; Voorhorst-Ogink, M. M.; Bolt-de Vries, J.; van Rooij, H. C.; Trapman, J.; Mulder, E. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids Biochim. Biophys. Acta 1990, 1052 (1) 187-94
49. Zhao, X. Y.; Malloy, P. J.; Krishnan, A. V.; Swami, S.; Navone, N. M.; Peehl, D. M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat. Med. 2000, 6 (6) 703-6
50. Guo, Z.; Yang, X.; Sun, F.; Jiang, R.; Linn, D. E.; Chen, H.; Chen, H.; Kong, X.; Melamed, J.; Tepper, C. G.; Kung, H. J.; Brodie, A. M.; Edwards, J.; Qiu, Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res. 2009, 69 (6) 2305-13
51. Hornberg, E.; Ylitalo, E. B.; Crnalic, S.; Antti, H.; Stattin, P.; Widmark, A.; Bergh, A.; Wikstrom, P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival PLoS One 2011, 6 (4) e19059
52. Culig, Z.; Comuzzi, B.; Steiner, H.; Bartsch, G.; Hobisch, A. Expression and function of androgen receptor coactivators in prostate cancer J. Steroid Biochem. Mol. Biol. 2004, 92 (4) 265-71
53. Cai, C.; Wang, H.; Xu, Y.; Chen, S.; Balk, S. P. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer Cancer Res. 2009, 69 (15) 6027-32
54. Decker, K. F.; Zheng, D.; He, Y.; Bowman, T.; Edwards, J. R.; Jia, L. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions Nucleic Acids Res. 2012, 40 (21) 10765-79
55. Hu, R.; Dunn, T. A.; Wei, S.; Isharwal, S.; Veltri, R. W.; Humphreys, E.; Han, M.; Partin, A. W.; Vessella, R. L.; Isaacs, W. B.; Bova, G. S.; Luo, J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res. 2009, 69 (1) 16-22
56. Chouinard, S.; Barbier, O.; Belanger, A. UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells J. Biol. Chem. 2007, 282 (46) 33466-74